High level expression of the nm23-Hl gene, which encodes for a nucleoside diphosphate kinase, has been found to correlate with diminished metastasis in some tumors but not in others. We have previously identified the protein product of the nm23-H1 gene in two-dimensional electrophoretic gels and have designated it p19/nm23. In neuroblastoma, higher levels of p19/ nm23, which are associated with amplification of the N-myc oncogene, large tumor mass, and metastasis, were observed in advanced stage tumors compared with limited stage disease. Because of the variable expression of nm23-H1 in different tumors, we have investigated the relationship between amounts of the protein and cell proliferation. The levels of p19/nm23 were compared between resting and mitotically stimulated normal human PBLs and in leukemia cells. The amount of p19/ nm23 increased in normal lymphocytes in response to mitotic stimulation and paralleled the increase in DNA synthesis. In leukemia cells obtained from patients with different subtypes of acute leukemia, p19/nm23 levels were also increased relative to resting normal lymphocytes. Treatment of mitotically stimulated lymphocytes with cyclosporin, which inhibits proliferation, blocked the increase in pl9/nm23; treatment of the leukemia cell line HL-60 with dimethylsulfoxide, which induces terminal differentiation, resulted in diminished levels of p19/nm23. Our data therefore provide evidence that nm23-Hl expression is related to cell proliferative activity. (J. Clin. Invest. 1992. 89:919-924.)
Introduction
The factors responsible for tumor proliferation and spread to distant sites remain ill defined. The gene nm23-Hl has been proposed as a candidate tumor metastasis suppressor on the basis of initial findings in certain tumors (1) . In human infiltrating ductal breast carcinomas and in model systems of rodent metastasis, nm23 RNA levels were lower in highly metastatic cells than in tumor cells oflow metastatic potential (2, 3) . Primary tumors that expressed high levels of nm23 mRNA, as determined by hybridization to murine nm23 cDNA, were associated with a relatively favorable prognosis relative to similar tumors with low levels of nm23 mRNA (4) . Transfection of a murine nm23 expression construct into highly metastatic K-1735 TK murine melanoma cells resulted in reduced incidence of primary tumor formation, reduced tumor metastatic potential, and altered responses to the cytokine transforming growth factor f,8 (5) . In contrast to these results, nm23 expression, as determined by Northern blot analysis, was reported to be increased in colonic neoplasms relative to morphologically normal colon mucosa, with no association demonstrated between expression and metastatic potential (6) . Furthermore, we have observed that the protein product of nm23-H 1 occurs in greater amounts in advanced neuroblastoma tumors that are associated with N-myc oncogene amplification and metastasis than in limited-stage tumors with a single copy of the N-myc gene (7) .
In our previous studies, we initially identified the protein product of the nm23-H 1 gene in two-dimensional electrophoretic gels of neuroblastoma cell proteins and designated it p 19/ nm23 (7) . We also previously detected this polypeptide in a variety of human cell lines, including lymphoid, myeloid, rhabdoid, colon, breast, and neural derived (8) . The occurrence of pl9/nm23 was not limited to malignant cell lines and tumors, since it was present in reduced amounts in unstimulated normal PBMCs. The mol wt ofpl9/nm23 was estimated to be 19,000, based on the migration in two-dimensional gels of unmodified, neighboring polypeptides for which the full amino acid sequence is known. Three pl9/nm23 internal peptides, which we sequenced, matched exactly the deduced sequence of nm23-Hl (7) .
nm23-H 1 is highly homologous to a Dictyostelium discoideum nucleoside diphosphate (NDP)' kinase (9) and to the Drosophila abnormal wing discs (awd) gene product (10) and is identical to human NDP kinase A (11) . Functional association of NDP kinase with G-proteins or Ras has been described (12, 13) and NDP kinase activity copurifies with ribonucleotide reductase, a key enzyme of deoxyribonucleotide synthesis (14) . Thus, nm23-H 1 could play a role in signal transduction or in DNA synthesis. In view ofthe identified function of nm23-H I and ofits variable expression in tumors, we have examined the relationship between levels ofpl 9/nm23 protein and cell proliferation. Because lymphoid cells can be manipulated with respect to their proliferative activity, they were relied on to determine the relationship between pl9/nm23 levels and normal and malignant cell proliferation.
Methods
Sources of cells. Normal lymphocytes were isolated from peripheral blood of healthy volunteers by Ficoll-Hypaque gradient centrifugation and-grown in RPMI 1640 medium supplemented with 10% FCS, 0.8% L-glutamine (29.2 ,g/ml), and 1% of penicillin/streptomycin (10, 000 IU/ml and 10 mg/ml, respectively Two-dimensional (2-D) PAGE. Cell pellets were solubilized by addition oflysis buffer consisting of(per liter) 8 M urea, 20 ml ofNonidet P-40 surfactant, 20 ml ofampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and 0.2 mM of PMSF in distilled deionized water. 2-D PAGE, silver staining, spot detection, and quantification were performed as previously described (7) .
Identity ofpl 9/nm23 by Western blot. The identity ofpl9/nm23 as NDP kinase A was determined by Western blotting oftwo-dimensional gels as previously described (7) using an antiserum raised against NDPkinase A (1 1).
Proliferation assay. Normal PBLs treated with PHA as above were labeled with [3H]thymidine for 4 h, using 1 ACi/50,000 cells per well, before harvesting at designated times. DNA content was performed using standard propidium iodide staining techniques (16) . Flow cytometry. Normal PBLs were divided into two aliquots: one was incubated for the stated time in RPMI 1640 supplemented with 5% FCS without PHA, and the second was stimulated with 1 sg/ml PHA. After harvesting and washing with PBS, the cells were fixed with 0.5% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 in PBS at room temperature for 10 min, and then washed twice with PBS. Antibody (1:1,000) against human erythrocyte NDP kinase A ( 11) was added for 4 h at 4VC. The cells were subsequently washed three times with cold PBS, the final wash containing PBS with 1% goat serum. Goat anti-rabbit FITC-conjugated antibody (Sigma Chemical Co., St. Louis, MO) was added at 1:60 for 1 h, then the cells were washed three times with cold PBS before flow cytometry. Flow cytometric analysis of 5,000 cells was performed on a C cell sorter (Epic Inc., New York, NY).
Results
Relationship between pl9/nm23 levels and cell proliferation. Freshly isolated normal PBLs were mitotically stimulated with PHA and their cellular proteins analyzed by 2-D PAGE to determine the relationship between cell proliferation and p19/ nm23 levels. Cellular [3H]thymidine uptake and flow cytometric analysis of cell DNA content were also determined as measures of proliferative activity. After PHA stimulation, p19/ nm23 increased from a faint to a prominent spot in silver-stained gels (Fig. 1 (18) . Similar increases in p19/nm23 were observed after stimulation of PBLs with an anti-CD3 antibody (OKT3, data not shown).
To further determine the extent of change in pl9/nm23 levels in maximally proliferating lymphoid cells in culture, we quantified the level of pl9/nm23, by 2-D PAGE, in proliferating Epstein-Barr virus-transformed B cells harvested during the logarithmic growth phase. The mean integrated intensity of 28 single cell-derived B cell clones was equivalent to the mean observed for PHA-stimulated T cells (Table I) , providing evidence that the increase in the level ofpl9/nm23 with proliferation is not limited to any one subtype of lymphocytes. We also determined the effect ofinhibiting lymphoid proliferation with cyclosporin (19) on p19/nm23 levels. In contrast to an increase in pl9/nm23 observed after treatment of PBLs with OKT3 alone, addition of cyclosporin prevented any increase in p19/ nm23 levels in response to OKT3 treatment.
Reactivity ofpl 9/nm23 with an antibody to NDP kinase A.
Western blot analysis ofproteins from resting and proliferating normal lymphocytes and from leukemic cells separated by 2-D PAGE was performed using a polyclonal rabbit antiserum against the human NDP kinase A (11) . This antibody preparation reacted exclusively with one polypeptide spot that corresponded to p I 9/nm23, further confirming the identity of p 19/ nm23 and also suggesting absence of modified forms with altered charge and/or mol wt in any of the cell types analyzed. (Fig. 3) from patients at the time of diagnosis were statistically signil cantly higher than in unstimulated normal PBLs and corr sponded to the levels observed in nonmalignant proliferatix lymphoid cells we have studied (Table I ). There was no signil bgo. I 1!_1 cant difference in the amount of p19/nm23 between the two major subtypes of ALL, namely, T and pre-B ALL. The mean p19/nm23 level in the ANLL group, represented predominantly by leukemias ofmyeloid origin, was significantly greater than that for ALL. We have examined the relationship between p1 9/nm23 levels and the mass of leukemic cells, as measured by the total peripheral white blood cell count at the time of diagnosis. There was no significant relationship between the level of pl9/nm23 and the white blood cell count for the total group of acute leukemia samples or for each of the three subgroups studied, suggesting that the tumor load in acute leukemia is not related to the level of pI9/nm23. The HL-60 myeloid leukemia cell line exhibited high levels of pI9/nm23. Treatment of HL-60 cells with DMSO or phorbol-12-myristate-13-acetate (PMA) is known to result in terminal differentiation to morphologically mature cells (22, 23) . In two separate experiments in which HL-60 cells were treated with DMSO for 40 h, we observed a decrease in the amount of pI9/nm23 as well as in the amount of other proliferation-related polypeptides that we have identified in 2-D gels (Fig. 4) . Similar results were obtained when HL-60 cells were treated with PMA (data not shown).
Discussion
The increase in p19/nm23 in response to mitogenic stimula- Recently, a second distinct human nm23 gene, designated nm23-H2, has been identified, which encodes for a peptide that is 88% identical to that of nm23-H 1 (24) . Levels of nm23-H2 were not reduced in highly metastatic breast tumors to the same extent as nm23-H 1 (24) . Gene nm23-H2 has been found to be identical to human erythrocyte NDP-kinase B (11), with a predicted pI of -9. On the basis of its pI, the protein product of nm23-H2 would be expected to migrate beyond the usual limits of carrier ampholyte-based 2-D gels and not to the position ofpl9/nm23. Thus, the sequence data we have generated, together with the pI of p19/nm23 and its exclusive reactivity with an antibody to human NDP kinase A, clearly indicate that p1 9/nm23 is identical with nm23-H 1 and not nm23-H2.
Several proteins other than pI9/nm23 are known to be expressed in a proliferation-related manner in late G1 and S phase. The proliferation-related increase in pI9/nm23 demonstrated in this study is ofinterest in relation to the proposed role for nm23 as a tumor metastasis suppressor gene (1) . In a separate study of neuroblastoma tumors, we observed statistically significantly higher levels of p19/nm23 in tumors from patients with advanced-stage disease than in tumors of limitedstage disease (7) . A highly significant correlation was also observed between p19/nm23 levels and amplification of the Nmyc oncogene, a feature associated with tumor progression and spread (26) . Thus, in our studies of p19/nm23, proliferating lymphoid cells and advanced-stage neuroblastoma tumor cells exhibited higher levels of the protein than did resting lymphocytes and limited-stage neuroblastoma tumors, respectively. These observations would suggest involvement ofNDP kinase/ p19/nm23 in normal and malignant proliferation that is distinct from its proposed role as a tumor metastasis suppressor.
It is of interest that the protein products of two other genes that play a role in tumor suppression, namely, p53 and RBl, have been found to undergo modification or to increase in amount in normal cells that have been induced to proliferate (27) (28) (29) . Mutated forms of p53 and RBl are associated with malignant proliferation (30, 31) . To date there has been no evidence for mutant forms of nm23-H 1. Carbone et al. (32) have sequenced the full open reading frame for nm23 in 10 small-cell lung cancer lines and have not found coding mutations. Our studies of neuroblastoma and leukemia indicate absence of a mutation in the nm23-H 1 gene that would have altered the pI or molecular weight of the protein product as determined by 2-D PAGE. On the basis of our findings, the relationship between nm23-H 1 levels and proliferative activity should be taken into consideration to allow a critical assessment of the role of nm23-H 1 in tumor cell metastasis.
